Document:

Retention Agreement between Bristol-Myers Squibb Company & Peter Kasper Jakobsen

 Exhibit 10.3 
 PERSONAL & CONFIDENTIAL AGREEMENT 
 Peter Kasper Jakobsen 
 1933 Camias Village 
 Dasmarinas Village 
 Makati City, Philippines 1231 
 Dear Peter: 
 On behalf of Bristol-Myers Squibb Company (“BMS”), I am pleased to offer you this Letter Agreement. If the BMS Board of Directors decides to proceed with a
sale, spin off, divestiture or other disposition (hereinafter, collectively the “Transformation”) of Mead Johnson Nutritionals (the “Business”), you are being offered the following incentives to ensure that the Business is
managed and operated efficiently throughout the process, the terms and conditions of which are outlined herein: 
  

	1.	Special Performance Bonus Amount. You will be eligible to receive a special cash performance bonus equal to your regular BMS target bonus level (“Special Bonus”) in
effect as of the closing date related to the Transformation of the Business (“Transformation Closing Date”) as follows: 

  

	 	(a)	If your employment transfers to a Successor (i.e., a third party purchaser of the Business or a spin-off of the Business, hereinafter “Successor”) as of the Transformation
Closing Date, you will be paid the Special Bonus as follows: 

  

	 	i.	50% of the Special Bonus will be paid to you within thirty (30) business days following the Transformation Closing Date, and 

  

	 	ii.	The remaining 50% of the Special Bonus will be paid within thirty (30) business days following the six (6) month anniversary of the Transformation Closing Date provided
that you either: (A) remain continuously employed by the Successor, or (B) you are involuntarily terminated other than for cause by the Successor prior to the six (6) month anniversary of the Transformation Closing Date (and in such
case you will be paid the remaining 50% of the Special Bonus within thirty (30) business days of your termination). 

	 	(b)	If you remain an employee of BMS after the Transformation Closing Date, you will be paid the Special Bonus as follows: 

  

	 	i.	50% of the Special bonus will be paid to you within thirty (30) business days following the Transformation Closing Date, and 

  

	 	ii.	You will not be eligible for the remaining 50% of the Special Bonus. 

  

	 	(c)	The Special Bonus will not be paid if, for any reason, the Transformation is canceled. Further, if you seek out and transfer to another position at BMS or the Business prior to the
Transformation Closing Date, the Special Bonus will not be paid. The Company retains the right, in its sole discretion, to provide the initial 50% of the Special Bonus to you if you have been asked by the Company to assume other responsibilities
prior to the Transformation Closing Date, 

  

	2.	Annual Bonus. Provided that you remain an active employee with the Business through the Transformation Closing Date and your employment is transferred to the Successor, you
will be eligible for a pro rata cash bonus at your target bonus level in effect at the time of the Transformation Closing Date, payable in one lump sum for all full or partial months worked during the calendar year in which the date of the transfer
of your employment to the Successor occurs. Other than your right to pro-rata payment under the terms and conditions of this Letter Agreement, the Annual Bonus will be subject to the terms and conditions of the applicable BMS annual bonus plan in
effect as of the transfer date. Such amounts shall be paid within five (5) business days following your “separation from service” from BMS (within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the
“Code”) and final Treas. Reg. §1.409A-1(h)(1)(ii)) (“Separation from Service”). If you remain an employee of BMS after the Transformation Closing Date, you will not be entitled to the pro rata annual bonus contemplated
by this paragraph 2, but you will remain eligible for a bonus under the terms of the applicable BMS bonus plan then in effect. 

  

	3.	 Enhanced Severance Payments. You will be eligible for enhanced severance payments if your employment is transferred to the Successor as a result of the
Transformation and your employment is then involuntarily terminated for reasons other than for cause by the Successor prior to the twelve (12) month anniversary date of the Transformation Closing Date. If your employment is terminated under
these circumstances, you will be eligible for the greater of: (i) a total of fifty-two (52) weeks of your base pay in effect as of the date of your termination, or (ii) the severance payments under the applicable BMS severance plan in
effect as of the date of your termination. If there are any severance payments available to you from the Successor, you will receive the difference between those severance payments and the severance payments available to you under this paragraph.
Payments under this Paragraph 3 shall commence immediately after your Separation from Service and shall be payable at regular payroll intervals according to your pay schedule then in effect. The enhanced severance payments described above, if
greater than those you would ordinarily have been entitled to, 

  

 2 

	 	 
will be in lieu of, and not in addition to, the severance (if any) that would ordinarily have been payable to you under the terms of the applicable BMS
Severance Plan or in any offer letter or other arrangement between you and BMS. 

  

	4.	Conditions of this Letter Agreement & General Release. The incentive payments and benefits described in this Letter Agreement in paragraphs 1 through 3 above are
contingent upon all of the following conditions: (a) the Transformation Closing Date occurring on or before April 20, 2009; (b) you are an employee in good standing (i.e., meeting the company’s performance expectations) of BMS as
of the Transformation Closing Date; (c) your honoring the need for strict confidentiality regarding the Transformation and the terms of this Letter Agreement, neither of which should be discussed with anyone other than your significant other,
financial or legal advisors without the express and specific permission of a designee of BMS; (d) your providing full support and cooperation in the best interests of BMS and the Business up to and including the Transformation Closing Date; and
(e) throughout the course of your continued employment with BMS and following the completion of the Transformation and/or your separation from BMS, if applicable, your taking no action which would be considered contrary to the best interests of
BMS, the Business, or their affiliates. 

 If you are on an unpaid leave of absence from BMS for more than thirty
(30) calendar days at any time between the date of this Letter Agreement and the Transformation Closing Date, all bonuses as described in paragraphs 1 and 2 will be pro-rated, if permissible under applicable law. A paid approved leave of
absence, as specified in the applicable BMS annual bonus plan in effect as of the Transformation Closing Date, will not impact your eligibility for the bonuses described in paragraphs 1 and 2 above. 
 Should termination indemnities or other payments mandated by any local laws become payable upon termination of your employment with the Business, you
agree to forfeit your rights in writing to all such payments or, if you receive such payments, you will immediately return them to BMS. In the event the waiver of such payments is unenforceable under local law, you agree to fully offset the value of
such payments due to you from other plans or benefits under which you may be eligible. 
 Finally, in order to receive any of the benefits
described in this Letter Agreement, you will be required to sign, timely return, and not revoke, a Separation Agreement which will include a general release of all claims (in a form satisfactory to BMS), well as other provisions, including, but not
limited to, certain restrictive covenants, which will be provided to you as soon as practicable on or around the Transformation Closing Date. 
  

 3 

	5.	Non-Solicitation. As a condition of your receipt of any payments or benefits under this Letter Agreement, commencing on the date of this Letter Agreement and ending on the
date which is one (1) year from the date of your separation from BMS and/or the transfer of your employment to a Successor, (the “Non-Solicitation Period); you will not, directly or indirectly, solicit for employment, hire, employ or
retain in any capacity, including, but limited to, as an employee, director, independent contractor, consultant or otherwise, other than for employment within BMS or its affiliates, any person who is employed or otherwise engaged on a full or
part-time basis by BMS and/or its affiliates during the Non-Solicitation Period. If you breach this provision, you will pay to BMS the sum of Ten Thousand Dollars ($10,000) for each act of solicitation, not as a penalty, but as liquidated damages
for injuries which precise economic value would be difficult to ascertain. 

 Additionally, you understand and agree that as
part of the Transformation process, BMS and/or the Business may place certain restrictions on certain third-parties prohibiting them from soliciting and or employing employees of the Business and/or BMS and you acknowledge that such restrictions are
permissible. 
  

	6.	Material Breach. Breach the terms of paragraphs 4 or 5 of this Letter Agreement and/or any provisions in the General Release shall constitute a material breach of this Letter
Agreement for which BMS or its affiliates may seek all relief available under the law. 

  

	7.	Not an Employment Agreement. Nothing in this agreement should be construed as a promise of employment for any particular time period. You are and remain an employee at will.

  

	8.	Withholding. It is understood and agreed that all amounts, payments or benefits payable to you as described in this Letter Agreement represent gross amounts and BMS is hereby
authorized to withhold any and all applicable withholdings and taxes from any such amounts, payments or benefits. 

  

	9.	Agreement Applicable in the Context of Change in Control of BMS. In the event of a “change in control” (as such term is defined under the Bristol-Myers Squibb
Company Change In Control Separation Benefits Plan and/or an individual change in control agreement held by you, if applicable), (i) paragraphs 2 and 3 of this Letter Agreement shall automatically be terminated and be null and void as of the
effective date of such “change in control”, and (ii) paragraphs (1) and paragraphs 4 through 15 shall remain in full force and effect. 

  

	10.	Governing Law; Jurisdiction. This Letter Agreement will be governed by and construed under the laws of the State of New York, without regard to its principles of conflict of
laws. If at any time after the date of this Letter Agreement any provision is held to be illegal, void, or unenforceable, that provision will have no force and effect. However, the illegality or unenforceability of that provision will not have any
effect on, and will not impair the enforceability of any other provision of this Letter Agreement. If a court of competent jurisdiction finds that the General Release is illegal and/or unenforceable, you will be required to execute a form general
release that is legal and enforceable. 

  

 4 

	11.	Amendment/Waiver. No provision in this Letter Agreement may be amended unless agreed to in writing and signed by you and an authorized officer of BMS.

  

	12.	Supersedes All Prior Agreements & Exclusive Retention Benefit. You acknowledge and agree that this Letter Agreement supersedes any and all other prior agreements
entered into between you and BMS with regard to the subject matter hereof, whether written or oral. In the event that any or all other employees of the Business receive or are offered a retention or similar bonus payable upon the Transformation
Closing Date and/or in connection with the Transformation, you understand and agree that you will not be eligible to receive such retention or similar bonuses or benefits, except as explicitly set forth in this Letter Agreement, or as amended
consistent with paragraph 11, above. 

  

	13.	No assignments. You may not assign or delegate any rights or obligations hereunder. BMS may assign this Letter Agreement or delegate any rights hereunder without your consent
to any successor in interest. 

  

	14.	Section 409A. If you are a “specified employee,” as determined by BMS in accordance with the requirements of Code Section 409A(a)(2)(B)(i), then upon your
Separation From Service, payments due to you under this Agreement that are deemed “nonqualified deferred compensation” under Code Section 409A and the final Treasury regulations thereunder (and do not meet any of the exemptions under
Code Section 409A and the final regulations thereunder) shall be delayed until the earlier of (i) six months following the date of your Separation From Service or (ii) the date of the your death. To the fullest extent possible,
amounts and other benefits payable under this Agreement are intended to be exempt from the definition of “nonqualified deferred compensation” under Code Section 409A in accordance with one or more exemptions available under the final
Treasury regulations promulgated under Code Section 409A and, to the extent that any such amount or benefit is or becomes subject to Code Section 409A due to a failure to qualify for an exemption from the definition of “nonqualified
deferred compensation” in accordance with such final Treasury regulations, this Agreement is intended to comply with the applicable requirements of Code Section 409A with respect to such amounts or benefits. This Agreement shall be
interpreted and administered to the extent possible in a manner consistent with the foregoing statement of intent. In no event whatsoever shall BMS or any of its affiliates be liable for any additional tax, interest or penalties that may be imposed
on you or your beneficiary or estate by Code Section 409A or any damages for failing to comply with Code Section 409A. 

  

	15.	Construction & Interpretation. Any determinations by BMS under this Letter Agreement including, but not limited to, determinations regarding eligibility for payments
and benefits hereunder shall be in the sole and absolute discretion of BMS and shall be conclusive and binding on all interested parties. 

  

 5 

 Please acknowledge your understanding of and agreement to the provisions of this Letter Agreement by signing and
returning this letter to me by November 7, 2007. 
  

	
	Very truly yours,
	
	/s/ John Celentano
	 John Celentano
 President, Health Care
Group
 Bristol-Myers Squibb Company

	
	AGREED TO AND ACCEPTED:
	
	/s/ Peter Kasper Jakobsen
	 Peter Kasper Jakobsen

 DATE: 05-11-2007 
  

 6 

 AMENDMENT TO LETTER AGREEMENT 
 August 11, 2008 
 Peter Kasper Jakobsen 
 1933 Camias Village 
 Dasmarinas Village 
 Makati City, Philippines 1231 
 Dear Peter: 
 On
behalf of Bristol-Myers Squibb Company (“BMS” or the “Company”), I am pleased to inform you that BMS has approved certain enhancements to the letter agreement between you and BMS, dated November 5, 2007 (the “Letter
Agreement”), which offered you certain incentives to ensure that Mead Johnson (the “Business”) is managed and operated efficiently throughout the process of the Transformation of the Business. First, this Amendment to the Letter
Agreement (“Amendment”) provides clarity that the definitions of Transformation and Successor include an initial public offering or partial public offering of at least ten percent (10%) (“IPO”) of the Business. Second, the
Effective Date of the Letter Agreement has been extended to December 31, 2009. Third, if the BMS Board of Directors determines not to proceed with an IPO of the Business prior to December 31, 2009, you will remain eligible for the entirety
of the Special Bonus and it will no longer be canceled under such circumstances. Fourth, this Amendment explicitly provides that the method of calculating the Special Bonus will be based on your regular BMS target bonus level and any future bonuses
for performance periods post-IPO will be based on the applicable bonus plans of the Business that take effect on or after the IPO. Fifth, the enhanced severance payment has been extended for involuntary terminations for reasons other than for cause
by the Successor to an eighteen (18) month period following the anniversary date of the Transformation Closing Date, which has been increased from a twelve (12) month period. Furthermore, if your employment is terminated under such
circumstances, you will now be eligible for the greater of: (i) a total of eighteen (18) months of your base pay in effect as of the date of such termination, which has been increased from twelve (12) months of your base pay, or
(ii) the severance payments under the applicable BMS severance plan in effect as of the date of such termination. It has also been clarified that, if there are any severance payments available to you from the Successor, you will receive the
greater of those severance payments or the severance payments available to you under the paragraph relating to the enhanced severance payment, but not both. Finally, if an IPO of the Business occurs prior to December 31, 2009, and you are an
employee of the Business after the Transformation Closing Date, you will also remain eligible for benefits under the Bristol-Myers Squibb Change In Control Separation Benefits Plan (“BMS CIC Plan”), provided benefits under the BMS CIC Plan
are available to similarly situated employees at your grade level or its equivalency at Bristol-Myers Squibb Company. 
 Capitalized terms not otherwise
defined or modified herein have the meanings ascribed to them in the Letter Agreement. 
 The definitions of “Transformation” and
“Successor” in the Letter Agreement are hereby amended to include an IPO of the Business. 

 Paragraph 1(c) of the Letter Agreement is hereby amended in its entirety to read as follows: 
  

	 	(c)	(i) The Special Bonus will be paid if (A) the IPO is canceled by BMS prior to December 31, 2009, and (B) you are an active employee and in good standing of the
Business as of the date the decision to cancel the IPO is made. The Special Bonus will be paid approximately six (6) months following the date the decision is made to cancel the IPO, but in no event later than March 15th of the calendar
year following the date the decision to cancel the IPO is made, to comply with Internal Revenue Code Section 409A. 

 (ii)
The Special Bonus will not be paid in the event (A) you seek out and transfer to another position at BMS or the Business prior to the Transformation Closing Date, (B) the Transformation takes a form other than the IPO and is then canceled
prior to December 31, 2009; or (C) except as otherwise provided in paragraph 1(c)(i) above, the Transformation Closing Date does not occur on or before December 31, 2009. 
 (iii) The Company retains the right, in its sole discretion, to provide the initial 50% of the Special Bonus to you if you have been asked by the Company
to assume other responsibilities prior to the Transformation Closing Date in the time period described in paragraph 1(a)i. above. 
 Paragraph 1(d) is hereby
added to the Letter Agreement so as to immediately follow Paragraph 1(c) as follows: 
  

	 	(d)	In the event you are eligible for a Special Bonus under sub-section 1(a), 1(b) or 1(c)(iii), the calculation of the Special Bonus will be based on your regular BMS target bonus
level in effect immediately prior to the Transformation Closing Date. In the event you are eligible for a Special Bonus under subsection 1(c)(i), the calculation of the Special Bonus will be based on your regular BMS target bonus level in effect
immediately prior to the date the decision to cancel the IPO is made. In the event of an IPO, your target cash bonus for performance periods post-IPO will be based on the applicable bonus plans and programs in effect for Business employees and such
plans and programs will have no relevance to the calculation of the Special Bonus. 

 Paragraph 3 of the Letter Agreement is hereby amended in
its entirety to read as follows: 
  

	3.	Enhanced Severance Payments. You will be eligible for enhanced severance payments if your employment is transferred to the Successor as a result of the Transformation and
your employment is then involuntarily terminated for reasons other than for cause by the Successor prior to the eighteen (18) month anniversary date of the Transformation Closing Date. If your employment is terminated under these circumstances,
you will be eligible for the greater of: (i) a total of eighteen (18) months of your base pay in effect as of the date of your termination by the Successor, or (ii) the severance payments under the applicable BMS severance plan in
effect as of the date of your termination by the Successor. If there are any severance payments available to you from the Successor, you will receive the greater of those severance payments or the severance payments available to you under this
paragraph, but not both. Payments under this Paragraph 3 shall commence immediately after your Separation from Service by the Successor and shall be payable at regular payroll intervals according to your pay schedule then in effect. The enhanced
severance payments described above, if greater than those you would ordinarily have been entitled to, will be in lieu of, and not in addition to, the severance (if any) that would ordinarily have been payable to you under the terms of the applicable
BMS Severance Plan or in any offer letter or other arrangement between you and BMS. 

  

 2 

 Paragraph 4 of the Letter Agreement is hereby amended in its entirety to read as follows: 
  

	4.	Conditions of this Letter Agreement & General Release. The incentive payments and benefits described in this Letter Agreement in Paragraphs 1 through 3 above are
contingent upon all of the following conditions: (a) the Transformation Closing Date occurring on or before December 31, 2009, except as otherwise provided in paragraph 1(c)(i) above; (b) you are an employee in good standing (i.e.,
meeting the company’s performance expectations) of BMS as of the Transformation Closing Date; (c) your honoring the need for strict confidentiality regarding the Transformation; (d) your honoring the need for strict confidentiality
regarding the terms of this Letter Agreement, which should not be discussed with anyone other than your significant other, financial or legal advisors without the express and specific permission of a designee of BMS; (e) your providing full
support and cooperation in the best interests of BMS and the Business up to and including the Transformation Closing Date; and (f) throughout the course of your continued employment with BMS and following the completion of the Transformation
and/or your separation from BMS, if applicable, your taking no action which would be considered contrary to the best interests of BMS, the Business, or their affiliates. 

 If you are on an unpaid leave of absence from BMS for more than thirty (30) calendar days at any time between the date of this Letter Agreement and
the Transformation Closing Date, all bonuses as described in Paragraphs 1 and 2 will be pro-rated, if permissible under applicable law. A paid approved leave of absence, as specified in the applicable BMS annual bonus plan in effect as of the
Transformation Closing Date, will not impact your eligibility for the bonuses described in Paragraphs 1 and 2 above. 
 Should termination
indemnities or other payments mandated by any local laws become payable upon termination of your employment with the Business, you agree to forfeit your rights in writing to all such payments or, if you receive such payments, you will immediately
return them to BMS. In the event the waiver of such payment is unenforceable under local law, you agree to fully offset the value of such payments due to you from other plans and programs or benefits under which you may be eligible. 
 Finally, in order to receive any of the benefits described in this Letter Agreement, you will be required to sign, timely return, and not revoke, a
Separation Agreement which will include a general release of all claims (in a form satisfactory to BMS), as well as other provisions, including, but not limited to, certain restrictive covenants, which will be provided to you as soon as practicable
on or around the Transformation Closing Date. 
 Paragraph 9 of the Letter Agreement is hereby amended in its entirety to read as follows: 
  

	9.	Agreement Applicable in the Context of Change in Control of BMS. In the event of a “change in control” (as such term is defined under the Bristol-Myers Squibb
Company Change In Control Separation Benefits Plan (“BMS CIC Plan”) prior to the Transformation Closing Date, this Letter Agreement shall automatically be terminated and be null and void as of the effective date of such “change in
control.” If the Transformation (i) is an IPO of the Business, (ii) the Business becomes and/or remains a subsidiary of BMS, and (iii) you remain an employee either of BMS or of the Business after the Transformation Closing Date,
you will remain eligible for benefits under the BMS CIC Plan if a change in control of BMS occurs, provided that benefits under the BMS CIC Plan are available to similarly situated employees in your grade level or its equivalency at BMS. In no case,
however, will you be eligible for benefits under the BMS CIC Plan if a change in control of the Business occurs. 

  

 3 

 All other provisions of the Letter Agreement remain unchanged and in full force and effect. 
 Pursuant to Paragraph 11 of the Letter Agreement, no provision of the Letter Agreement may be amended unless such amendment is agreed to in writing and signed by you and
an authorized officer of BMS. Accordingly, in order for the enhancements to the Letter Agreement set out in the Amendment to have effect, you must acknowledge your understanding of and agreement to the terms of the Amendment by signing and returning
this letter to me no later than August 25, 2008. 
  

	
	Very truly yours,
	
	/s/ Stephen W. Golsby
	 Stephen W. Golsby
 President, Mead Johnson
Nutritionals

	
	AGREED TO AND ACCEPTED:.
	
	/s/ Peter Kasper Jakobsen
	Peter Kasper Jakobsen

  

 4Bristol-Myers Squibb Company Change in Control Separation Benefits Plan

 Exhibit 10.8 
 Bristol-Myers Squibb Company 
 Change In Control Separation 
 Benefits Plan 
 and 
 Summary Plan Description 
  

			
	Separation Benefits Plan – Effective September 12, 2006	  	Bristol-Myers Squibb Company

			
	 Purpose
	  	1
		
	 Section 1 – Eligibility to Participate
	  	1
		
	 Section 2 – Eligibility for Separation Payments and Benefits
	  	1
		
	 Section 3 – Separation Payments And Benefits
	  	3
		
	 Section 4 – Successors to the Company
	  	6
		
	 Section 5 – Duration, Amendment and Plan Termination
	  	7
		
	 Section 6 – Miscellaneous
	  	8
		
	 Section 7 – Administrative Information About Your Plan
	  	11
		
	 Section 8 – Your Rights and Privileges Under ERISA
	  	12
		
	 Section 9 – Other Administrative Facts
	  	14

  

			
	Separation Benefits Plan – Effective September 12, 2006	  	Bristol-Myers Squibb Company

 Purpose 
 The Board of
Directors of Bristol-Myers Squibb Company (“BMS” or the “Company”) has adopted the Bristol-Myers Squibb Company Change In Control Separation Benefits Plan (the “Plan”) for eligible employees of the Company and its
participating subsidiaries and affiliates. The Board of Directors of the Company recognizes that any prospect of a Change in Control (as defined on page 10 below) may create uncertainties for employees with respect to their future employment
opportunities, compensation, benefits and conditions of employment. Because of the value of the services that employees of the Company render and the importance of their contributions to the success and profitability of the Company, the Company
believes that it is essential and in the best interest of the Company and its stockholders to adopt the Plan to provide eligible employees with additional security to reduce adverse effects on employees’ performance and morale in the event of a
Change in Control. The Company further believes that the Plan will aid the Company in attracting and retaining highly qualified individuals who are essential to its success. 
 Section 1 – Eligibility to Participate 
 You are eligible to participate in the Plan if you are: (i) an
employee of the Company or a Participating Employer employed in the United States or Puerto Rico or a U.S. “expatriate” at a Company location abroad; (ii) you are below the E7 level; and (iii) you are scheduled to work for the
Company or a Participating Employer at least fourteen (14) hours each week (an “Eligible Employee”). 
 Notwithstanding anything contained
herein, you are not eligible to participate in the Plan and are excluded from coverage under the Plan if you are a party to an individual arrangement or a written employment agreement containing a change-in-control provision that provides for
separation payments in connection with a change in control or you are covered by the terms of a collective bargaining agreement. In addition, if you are performing services for the Company or a Participating Employer as a leased worker (employed and
paid by another company), independent contractor or consultant, you are not eligible for payments or benefits under the Plan, even if you are later deemed by a court or any government agency to be a common law employee of the Company or a
Participating Employer. 
 Section 2 – Eligibility for Separation Payments and Benefits 
 Right to separation payments and benefits 
 You shall be eligible to
receive from the Company separation payments and benefits as set forth in Section 3 if: (i) there has been a Change in Control; and (ii) within three (3) years after the effective date of such Change in Control, your employment
by the Company, a Participating Employer, a controlling entity or a successor entity is terminated, voluntarily or involuntarily for any one or more of the following reasons: 
  

	 	(a)	Your employment is terminated involuntarily, other than for Cause, unless you are offered employment for which you are qualified by reason of knowledge, training or experience with
a controlling entity or a successor entity. 

  

 1 

			
	Separation Benefits Plan – Effective September 12, 2006	  	Bristol-Myers Squibb Company

	 	(b)	You voluntarily terminate your employment within sixty (60) calendar days after the occurrence of any one or more of the following events: 

  

	 	(1)	Your base salary that was in effect immediately before the Change in Control is reduced. 

  

	 	(2)	Your annual cash bonus is decreased below the amount which would have been payable under the bonus plan in which you participated immediately prior to the Change in Control had you
continued in employment until the end of the fiscal year of the Company, a controlling entity or successor entity, as appropriate, and had bonuses been payable at target levels for such year; provided that such reduction results in the aggregate of
your base salary and cash bonus being reduced below the level that was in effect immediately prior to the Change in Control. However, a reduction in bonus shall not include a change effected in the ordinary course of business that is applicable to
all similarly situated employees of the controlling entity or successor entity who are not former employees of BMS. 

  

	 	(3)	The location of your job or office is changed, so that you will be based at a location which is more than 50 miles further from your residence than was your work location
immediately before the Change in Control. 

  

	 	(4)	The overall benefits and perquisites available to you immediately before the Change in Control are reduced, including a material increase in the cost to you or your dependents for
such benefits or perquisites. Benefits include, without limitation, qualified or nonqualified defined benefit or defined contribution pension benefits; stock-based or annual incentive compensation programs; outplacement services; medical or dental
coverages; disability or life insurance coverages; severance benefits; or sick pay, vacation pay, paid holidays or paid leave of absence allowances. Perquisites include, without limitation, educational assistance, executive physical examinations,
expatriate income tax preparation services and car allowances. However, a reduction in benefits or perquisites shall not include a change effected in the ordinary course of business that is applicable to all similarly situated employees of the
controlling or successor entity who are not former employees of BMS. 

  

	 	(5)	A controlling entity or a successor entity fails or refuses to assume the Company’s obligations under the Plan. 

 Notwithstanding the above, if: (i) (A) your employment is terminated by the Company or a Participating Employer without Cause prior to the date of a Change in
Control or (B) an action is taken with respect to you prior to the date of a Change in Control that would cause you to be eligible for separation payment and benefits under Section 3 if taken after a Change in Control; and (ii) you
reasonably demonstrate that such termination or action (A) was at the request of a third party that has indicated an intention or taken steps reasonably calculated to effect a Change in Control, or (B) otherwise arose in connection with,
or in anticipation of, a Change in Control that has been threatened or proposed, such termination or action shall be deemed to have occurred after such Change in Control for purposes of the Plan, so long as such Change in Control actually occurs. If
any such termination or action occurs while an agreement is pending and the effective provisions of such agreement provide for a transaction or transactions which if consummated would constitute a Change in Control, then such termination or action
shall conclusively be presumed to have occurred in connection with a Change in Control. 
  

 2 

			
	Separation Benefits Plan – Effective September 12, 2006	  	Bristol-Myers Squibb Company

 Ineligibility for separation payments and benefits 
 You shall not be eligible for separation payments and benefits if your termination of employment occurs by reason of death, voluntary retirement other than for reasons specified above, voluntary termination other than
for reasons specified above, disability (as defined in the Company’s long-term disability plan as in effect immediately prior to a Change in Control), or for Cause. 
 Cause 
 “Cause” shall mean: 
  

	 	(i)	refusal by you to substantially perform your duties with the Company or a Participating Employer, e.g., job abandonment, (other than any such failure resulting from your incapacity
due to physical or mental illness) for a period of at least thirty (30) consecutive days after a written demand for substantial performance is delivered to you by the Company or a Participating Employer, which demand specifically identifies the
manner in which the Company believes that you have not substantially performed your duties; 

  

	 	(ii)	engaging by you in conduct which is demonstrably and materially injurious to the Company, its affiliates or its subsidiaries, monetarily or otherwise; or 

 

	 	(iii)	misconduct or activity deemed detrimental to the interests of the Company. This may include, but is not limited to, the following: acts involving dishonesty, violation of Company
policies (such as those related to alcohol or drugs, etc.), violation of safety rules, disorderly conduct, discriminatory harassment, unauthorized disclosure of Company confidential information, or the entry of a plea of nolo contendere to, or the
conviction of, a crime. 

 “Cause” shall be interpreted in such a way as to be consistent with the manner in which such term was
interpreted and applied by the Company under its applicable severance plans in effect prior to the Change in Control. 
 Section 3 – Separation
Payments And Benefits 
 Separation payments for employees below E7 
 If you are an Eligible Employee and one of the events described in Section 2 occurs, you shall be eligible to receive the greater of either: 
  

	 	(i)	six (6) months of base salary if you are below a “key executive” (i.e., below E4, E4M or their respective equivalents as determined by the Company) immediately
prior to the Change in Control or twelve (12) months of base salary if you are an E4, E4M, E5 or E6 employee or an employee at an equivalent executive level as determined by the Company immediately prior to the Change in Control; or

  

	 	(ii)	the greater cash severance payable, if any, under (A) the applicable severance plan of the controlling entity or successor entity that is in effect at the time you become
eligible for separation payments hereunder, (B) the applicable severance plan of the Company that is in effect on the effective date of the Plan, or (C) the applicable severance plan of the Company in effect immediately prior to the Change
in Control. 

  

 3 

			
	Separation Benefits Plan – Effective September 12, 2006	  	Bristol-Myers Squibb Company

 Nothing in this Section 3 or the Plan or in an offer letter from the Company shall entitle you to receive duplicate
benefits. For example, you are not eligible for payments and benefits under both this Plan and the Company’s severance plan in effect immediately prior to the Change in Control. 
 The base salary used in calculating the separation payments shall be the greater of: (i) the base salary in effect immediately prior to the Change in Control; or (ii) the base salary in effect immediately
prior to your employment by the Company being terminated for any reason specified in Section 2. 
 In addition, you will receive an amount equal to the
greater of: (i) the amount which would have been payable under the bonus plan in which you participated immediately prior to the Change in Control had you continued in employment until the end of the fiscal year of the Company, a controlling
entity or successor entity, as appropriate, and had bonuses been payable at target levels for such year; or (ii) the amount which would have payable under the bonus plan in which you participated on your termination date had you continued in
employment until the end of the fiscal year of the Company, a controlling entity or successor entity, as appropriate, in which your termination date occurs and had bonuses been payable at target levels for such year, multiplied by a fraction the
numerator of which is the number of whole and partial months that have elapsed in such fiscal year through your termination date (counting any partial month as a whole month for this purpose) and the denominator of which is twelve. 
 Pay in lieu of notice periods 
 The separation payments under the Plan
shall not be reduced by any cash payments to which you may be entitled under any federal, state or local plant-closing or mass layoff law (or similar or analogous) law, including, without limitation, pursuant to the U.S. Worker Adjustment and
Retraining Notification Act or any state or local “pay in lieu of notice” law or regulation. 
 Offset 
 The separation payments under the Plan shall be reduced (but not below zero) for employees in Puerto Rico by any payments under Puerto Rico Act 80, as amended on
October 7, 2005. The separation payments under the Plan shall be reduced (but not below zero) for “ex pats” with respect to any statutory payments of severance in any country other than the U.S. and the payments and benefits hereunder
are conditioned upon statutory payments, if any, being offset. 
 Period of separation payments 
 The separation payments you are eligible to receive shall be paid to you by the Company or the controlling entity or successor entity in substantially equal installments
at regular payroll intervals according to your pay schedule prior to termination, unless you begin work with a new employer prior to the expiration of your period of the separation payments. If you begin working for a new employer before your
separation pay period expires, you will receive any remaining separation payments as a single lump sum. It is your responsibility to advise the Company or controlling entity or successor entity, in writing, if your new employment will begin before
the expiration of the separation pay period. 
 Payments will commence on the first such payroll date after the Company receives your signed general release.

 General release 
 The obligation of the Company,
controlling entity or successor entity to make payments hereunder shall be conditioned upon the timely execution of a written general release of claims against the Company or a Participating Employer or controlling entity or successor entity in the
form customarily used by the Company immediately prior to the Change in Control, but with such changes as may be necessary to 

  

 4 

			
	Separation Benefits Plan – Effective September 12, 2006	  	Bristol-Myers Squibb Company

 
release the controlling entity, the successor entity and their affiliates and to ensure compliance with legal requirements. To be eligible to receive
separation payments, Company-subsidized medical, life and dental benefits and to the extent applicable other benefits as set forth below, you must execute and return a general release during the requisite time period. 
 If you do not return the executed general release to the Company, controlling entity or the successor entity during the requisite time period, the Company or successor
entity will consider this a refusal to sign it, and you will not be eligible to receive the separation payments and other benefits, as applicable. 
 No
mitigation 
 You shall not be required to mitigate the amount of any payment provided for in the Plan by seeking other employment or otherwise and no
such payment shall be offset or reduced by the amount of any compensation or benefits provided to you in any subsequent employment. 
 Other separation
benefits 
 Medical, Dental and Life Insurance Benefits 
 At termination of employment, you and your enrolled eligible dependents will be given the opportunity to continue your life, medical and dental benefits on a subsidized basis to the extent provided in the Company’s applicable severance
plan as in effect immediately prior to the Change in Control. 
 Management Stock Options 
 All outstanding unvested stock options (including options held less than one year) you hold under the 2002 Stock Incentive Plan (the “Stock Plan”) shall become
fully vested and exercisable in the event your employment is terminated during the three (3) years following a Change in Control and the termination is considered a “qualifying termination” (as defined under the Stock Plan).

 TeamShare Stock Options 
 Unvested stock options held
at least one year from the date of grant will receive accelerated vesting immediately following a Change in Control. These transactions are triggered solely by a Change in Control, whether or not you are terminated. 
 Restricted Stock 
 In the event your employment is terminated during
the three (3) years following a Change in Control and the termination is considered a “qualifying termination” (as defined under the Stock Plan), all restrictions on the restricted stock that you hold shall immediately lapse and the
restricted stock shall become fully vested, including restricted stock held less than one year. 
 Long-Term Performance Awards 
 In the event your employment is terminated during the three (3) years following a Change in Control and the termination is considered a “qualifying
termination” (as defined under the under the individual’s Long-Term Performance Award Agreement (LTPAA)), payout of outstanding awards under the LTPAA shall be made on a pro rata basis at the greater of target or projection. 
 Vesting of Company Matching Contributions 
 Unvested company matching
contributions under the Bristol-Myers Squibb Company Savings and Investment Program, Bristol-Myers Squibb Puerto Rico, Inc. Savings and Investment Program and U.S. BEP Savings Plan, as applicable, shall become fully vested upon a Change in Control.
(Employees with five or more years of service are fully vested in matching contributions and you are always vested in your own Savings Plan contributions.) 
  

 5 

			
	Separation Benefits Plan – Effective September 12, 2006	  	Bristol-Myers Squibb Company

 Vesting under the Retirement Income Plan 
 Unvested accrued benefits under the Bristol-Myers Squibb Company Retirement Income Plan, the Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income Plan and the U.S. BEP Retirement Income Plan, as applicable, shall
become fully vested upon a Change in Control. (Employees with five or more years of service are fully vested.) 
 The timely signing and returning of a
general release is required in order to receive the benefits described above with respect to Management Stock Options, Restricted Stock, Long-Term Performance Awards and vesting of Company matching contributions. 
 To the extent that there is a conflict between the terms of this Plan and the Stock Plan, LTPAA, Savings Plan and/or the TeamShare Stock Option Plan as it relates to
benefits under those plans, the terms of the Stock Plan, LTPAA, Savings Plan and/or the TeamShare Stock Option Plan, as applicable, shall govern. 
 Section 4 – Successors to the Company 
 This Plan shall bind any controlling entity and any successor entity (whether direct or
indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company. In the case of any transaction in which a controlling entity or a successor entity would not by the foregoing
provision or by operation of law be bound by the Plan, the Company shall require such entity expressly and unconditionally to assume and agree to perform the obligations under this Plan. 
 Section 5 – Duration, Amendment and Plan Termination 
 Duration 
 This Plan shall continue in effect until terminated in accordance with this Section 5. Notwithstanding the foregoing, if a Change in Control occurs, this Plan shall
continue in full force and effect, and shall not terminate or expire until such date as all employees who become entitled to receive separation payments and benefits hereunder shall have received such separation payments and benefits in full.

 Amendment and termination 
 Prior to a Change in
Control, the Plan may be amended or modified in any respect, and may be terminated, in any such case by resolution adopted by the Compensation and Management Development Committee of the Board of Directors of the Company or by its delegate;
provided, however, that no such amendment, modification or termination that would adversely affect the benefits or protections hereunder of any individual who is an employee as of the date such amendment, modification or termination is
adopted shall be effective as it relates to such individual unless no Change in Control occurs within one year after such adoption, any such attempted amendment, modification or termination adopted within one year prior to a Change in Control being
null and void ab initio as it relates to all such individuals who were eligible to participate in the Plan prior to such adoption (it being understood, however, that, the hiring, termination of employment, promotion or demotion of any
employee of the Company or any of its affiliates prior to a Change in Control shall not be construed to be an amendment, modification or termination of the Plan); provided, further, however, that the Plan may not be amended, modified or
terminated (i) at the request of a third party who has indicated an intention or taken steps to effect a Change in Control and who effectuates a Change in Control, or (ii) otherwise in connection with, or in anticipation of, a Change in
Control which actually occurs, any such attempted amendment, modification or termination being null and 

  

 6 

			
	Separation Benefits Plan – Effective September 12, 2006	  	Bristol-Myers Squibb Company

 
void ab initio. Any action taken to amend, modify or terminate the Plan which is taken after the execution of an agreement providing for a transaction
or transactions which, if consummated, would constitute a Change in Control shall conclusively be presumed to have been taken in connection with a Change in Control. From and after the occurrence of a Change in Control, the Plan may not be amended
or modified in any manner that would in any way adversely affect the benefits or protections provided hereunder to any individual who is eligible to receive separation payment and benefits under the Plan. 
 Section 6 – Miscellaneous 
 Legal fees and expenses

 The Company or the controlling or successor entity shall reimburse all legal fees, court costs and related expenses (including the costs of experts and
counsel) reasonably and in good faith incurred by you if you prevail on your claim for relief in an action by you to obtain or enforce any right or benefit provided by the Plan. 
 Employment status 
 The Plan does not constitute a contract of employment and nothing in the Plan says or implies that
participation in the Plan is a guarantee of continued employment with the Company or any of its affiliates. 
 Withholding of taxes 
 The Company or controlling entity or successor entity shall withhold from any amounts payable under the Plan all federal, state, local or other taxes that are legally
required to be withheld. 
 No effect on other benefits 
 Neither the provisions of this Plan nor the separation payments and benefits provided for hereunder shall reduce any amounts otherwise payable to you under any incentive, retirement, stock option, stock bonus, stock ownership, group
insurance or other benefit plan or arrangement. 
 Validity and severability 
 The invalidity or unenforceability of any provision of the Plan shall not affect the validity or enforceability of any other provision of the Plan, which shall remain in full force and effect, and any prohibition or
unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. 
 Settlement of claims 

 The Company’s or successor entity’s obligation to make the payments provided for in the Plan and otherwise to perform its obligations hereunder
shall not be affected by any circumstances, including, without limitation, any set-off, counterclaim, defense, recoupment, or other right which the Company may have against you or others. 
 Unfunded obligation 
 All separation payments and benefits under the
Plan shall constitute an unfunded obligation of the Company or the successor entity. Separation payments shall be made, as due, from the general funds of the Company. The Plan shall constitute solely an unsecured promise by the Company, the
controlling 

  

 7 

			
	Separation Benefits Plan – Effective September 12, 2006	  	Bristol-Myers Squibb Company

 
entity or the successor entity to provide such benefits to you to the extent provided herein. For avoidance of doubt, any health or stock benefits to which
you may be entitled under the Plan shall be provided under other applicable employee benefit plans of the Company, the controlling entity or the successor entity. Nothing in the Plan shall restrict the Company’s, the controlling entity’s
or the successor entity’s ability to amend, modify or terminate such other employee benefit plans (whether before or after a Change in Control). 
 Governing law 
 It is intended that the Plan be an “employee welfare benefit plan” within the meaning of Section 3(1) of the
Employee Retirement Income Security Act of 1974, as amended (“ERISA”), and the Plan shall be administered in a manner consistent with such intent. The Plan and all rights thereunder shall be governed and construed in accordance with ERISA
and, to the extent not preempted by Federal law, with the laws of the state of New York. 
 Section 409A 
 It is intended that the Plan comply with Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), if applicable, and, in the event that
the Plan is determined to be a “deferred compensation plan” within the meaning of Section 409A(d)(1) of the Code, the Company shall, as necessary, adopt such conforming amendments as are necessary to comply with Section 409A of
the Code without reducing the benefits due to participants hereunder. 
 Assignment 
 The Plan shall inure to the benefit of and shall be enforceable by your personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If you should die while any
amount is still payable to you under the Plan had you continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of the Plan to your estate. Your rights under the Plan shall not otherwise be
transferable or subject to lien or attachment. 
 Other benefits 
 Nothing in this document is intended to guarantee that benefit levels or costs will remain unchanged in the future in any other plan, program or arrangement of the Company. The Company and its affiliates and subsidiaries reserve the right
to terminate, amend, modify, suspend, or discontinue any other plan, program or arrangement of the Company or its subsidiaries or affiliates in accordance with such, plan, program and arrangement and applicable law. 
 Oral statements 
 The payments and benefits hereunder shall supercede
any oral statements made by any employee, officer or Board member of the Company, controlling entity or successor entity regarding change in control benefits. 
 Definitions 
 Base Salary means an employee’s base rate of pay, which excludes overtime, commissions, bonuses, income from stock
options, stock grants or other incentives, and any other forms of extra compensation. No foreign service allowance shall be included in determining the amount of severance payments payable under the Plan. 
  

 8 

			
	Separation Benefits Plan – Effective September 12, 2006	  	Bristol-Myers Squibb Company

 Change in Control means the occurrence of any of the following: 
  

	 	(i)	the date any Person (as defined in Section 13(d)(3) of the Securities and Exchange Act, as amended (the “Exchange Act”)) shall have become the direct or indirect
beneficial owner of thirty percent (30%) or more of the then outstanding common shares of the Company (the 30% threshold takes effect December 6, 2007 and a 20% threshold is in effect until December 6, 2007); 

 

	 	(ii)	the date of consummation of a merger or consolidation of the Company with any other corporation other than (A) a merger or consolidation which would result in the voting
securities of the Company outstanding immediately prior thereto continuing to represent at least fifty-one percent (51%) of the combined voting power of the voting securities of the Company or the surviving entity outstanding immediately after
such merger or consolidation (the 51% threshold takes effect December 6, 2007 and a 75% threshold is in effect until December 6, 2007); or (B) a merger or consolidation effected to implement a recapitalization of the Company in which
no Person acquires more than 50% of the combined voting power of the Company’s then outstanding securities; 

  

	 	(iii)	the date the stockholders of the Company approve a plan of complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all
the Company’s assets; or 

  

	 	(iv)	the date there shall have been a change in the composition of the Board of Directors of the Company within a two (2) year period such that a majority of the Board does not
consist of directors who were serving at the beginning of such period together with directors whose initial nomination for election by the Company’s stockholders or, if earlier, initial appointment to the Board was approved by the vote of
two-thirds of the directors then still in office who were in office at the beginning of the two (2) year period together with the directors who were previously so approved. 

 The term “Person” has the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof; however, a
Person shall not include (i) the Company or any of its subsidiaries, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its subsidiaries, (iii) an underwriter temporarily
holding securities pursuant to an offering of such securities, or (iv) a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company. 

Controlling Entity means any individual, entity or group whose acquisition of outstanding Bristol-Myers Squibb Company common stock (whether alone or with
other individuals, entities or groups) results in a Change in Control event, and the affiliates of any such individual, entity or group. 
 Successor
Entity means the successor to Bristol-Myers Squibb Company (or the assets thereof) following a Change in Control event, and the affiliates of any such entity. 
 Section 7 – Administrative Information About Your Plan 
 Employer identification number 
 Bristol-Myers Squibb Company’s employer identification number is #22-0790350. 
  

 9 

			
	Separation Benefits Plan – Effective September 12, 2006	  	Bristol-Myers Squibb Company

 Claim for benefits 
 If you believe you are entitled to payments and benefits under the Plan, then contact the Plan Administrator in writing. 
 Claims review
procedures 
 You will be notified in writing by the Company if you are denied payments and benefits under the Plan. 
 If a claim for benefits under the Plan is denied in full or in part, you* may appeal the decision to the Plan Administrator. To appeal a decision, you* must submit a
written document through the U.S. Postal Service or other courier service appealing the denial of the claim within 60 days after your termination of employment or you will no longer be eligible to receive benefits under the Plan. You* may also
include information or other documentation in support of your claim. You* will be notified of a decision within 90 days (which may be extended to 180 days, if required) of the date your appeal is received. This notice will include the reasons for
the denial and the specific provision(s) on which the denial is based, a description of any additional information needed to resubmit the claim, and an explanation of the claims review procedure. If an extension of time is required by the plan, you*
will receive notice of the reason for the extension within the initial 90-day period and a date by which you can expect a decision. 
 If the original denial
is upheld on first appeal, you* may request a review of this decision. You* may submit a written request for reconsideration to the Plan Administrator (as listed on the last page of this section) within 60 days after receiving the denial.

 You* can review all plan documents in preparing your appeal and you* may have a qualified person represent you* during the appeal process. Any documents
or records that support your position must be submitted with your appeal letter. 
 The case will be reviewed, and you* will receive written notice of the
decision within 60 days (which may be extended to 120 days, if required) including the specific reasons for the decision and specific reference to the plan provision(s) on which the decision is based. 
 Any decision on final appeal shall be final, conclusive and binding upon all parties. If the final appeal is denied, however, you will be advised of your right to file a
claim in court. It is the intent of the Company that the standard of review applied by a court of law or a professional arbitrator to any challenge to a denial of benefits on final appeal under these procedures shall be an arbitrary and capricious
standard and not a de novo review. 
 Legal action 
 You may not bring a lawsuit to recover benefits under the Plan until you have exhausted the internal administrative process described above. No legal action may be commenced at all unless commenced no later than one (1) year following
the issuance of a final decision on the claim for benefits, or the expiration of the appeal decision period if no decision is issued. This one-year statute of limitations on suits for all benefits shall apply in any forum where you may initiate such
a suit. 
  

	*	Or your duly authorized representative. 

  

 10 

			
	Separation Benefits Plan – Effective September 12, 2006	  	Bristol-Myers Squibb Company

 Participating employers 
 A complete list of Bristol-Myers Squibb Company, affiliates, subsidiaries or divisions that participate in the Plan may be obtained from the Plan Administrator by written request. (See the chart at the end of this section for the name and
address of the Plan Administrator.) 
 Plan Administrator 
 The administration of the Plan is the responsibility of the Plan Administrator. The Plan Administrator has the discretionary authority and responsibility for, among other things, determining eligibility for benefits and construing and
interpreting the terms of the Plan. In addition, the Plan Administrator has the authority, at its discretion, to delegate its responsibility to others. The chart at the end of this section contains the name and address of the Plan Administrator.

 Section 8 – Your Rights and Privileges Under ERISA 
 As a participant in the Plan, you are entitled to certain rights and protection under ERISA. ERISA provides that you shall be entitled to: 
 Receive information about your Plan and benefits 
 Examine, without charge, at the Plan Administrator’s office and at other specified
locations, such as worksites, all documents governing the plan, including a copy of the latest annual report (Form 5500 Series) filed by the plan with the U.S. Department of Labor and available at the Public Disclosure Room of the Employee Benefits
Security Administration. 
 Obtain, upon written request to the Plan Administrator, copies of documents governing the operation of the plan, including copies
of the latest annual report (Form 5500 Series) and updated summary plan description. The administrator may make a reasonable charge for the copies. 
 Receive a summary of the plan’s annual financial report. The Plan Administrator is required by law to furnish each participant with a copy of the summary annual report. 
 Prudent actions by Plan fiduciaries 
 In addition to creating certain rights for you, ERISA imposes duties upon the
people who are responsible for the operation of the employee benefit plan. The people who operate your plan, called “fiduciaries” of the plan, have a duty to do so prudently and in the interest of you and other plan participants and
beneficiaries. No one, including your employer, or any other person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a welfare benefit or exercising your rights under ERISA. 
 Enforce your rights 
 If your claim for a welfare benefit is denied or
ignored, in whole or in part, you have a right to know why this was done, to obtain copies of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules. 
 Under ERISA, there are steps you can take to enforce the above rights. For instance, if you request a copy of plan documents or the latest annual report from the plan
and do not receive them within 30 days, you may file suit in a Federal court. In such a case, the court may require the Plan Administrator to provide the materials and pay you up to $110 a day until you receive the materials, unless the materials
were not sent because of reasons beyond the control of the administrator. 
  

 11 

			
	Separation Benefits Plan – Effective September 12, 2006	  	Bristol-Myers Squibb Company

 If you have a claim for benefits which is denied or ignored, in whole or in part, you may file suit in a state or Federal
court. In addition, if you disagree with the plan’s decision or lack thereof concerning the qualified status of a medical child support order, you may file suit in a Federal court. 
 If it should happen that plan fiduciaries misuse the plan’s money, or if you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in
a Federal court. The court will decide who should pay court costs and legal fees. If you are successful the court may order the person you sued to pay these costs and fees. If you lose, the court may order you to pay these costs and fees, for
example, if it finds your claim is frivolous. 
 Assistance with your questions 
 If you have any questions about your plan, you should contact the Plan Administrator. If you have any questions about this statement or about your rights under ERISA, or if you need assistance in obtaining documents
from the Plan Administrator, you should contact the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone directory or the Division of Technical Assistance and Inquiries, Employee
Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue N.W., Washington, D.C. 20210. You may also obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the
Employee Benefits Security Administration at 1-866-444-EBSA (3272) or accessing their website at http://www.dol.gov/ebsa. 
 Section 9 – Other
Administrative Facts 
  

			
	Name of Plan	  	Bristol-Myers Squibb Company Change In Control Separation Benefits Plan
		
	Type of Plan	  	“Welfare” plan
		
	Plan Records	  	Kept on a calendar-year basis
		
	Plan Year	  	January 1 – December 31
		
	Plan Funding	  	Company and participating employers provide separation benefits from general revenues.
		
	Plan Sponsor	  	Bristol-Myers Squibb Company
		
	Plan Number	  	553
		
	Plan Administrator and Named Fiduciary	  	 Bristol-Myers Squibb Company
 c/o Senior Vice
President, Human Resources
 345 Park Avenue
 New York, NY 10154

 Telephone: (212) 546-4000

  

 12 

			
	Separation Benefits Plan – Effective September 12, 2006	  	Bristol-Myers Squibb Company

			
	Agent for Service of Legal Process on the Plan	  	 Bristol-Myers Squibb Company
 c/o Senior Vice
President and General Counsel
 345 Park Avenue
 New York, NY
10154
 Telephone: (212) 546-4000
  
 Bristol-Myers Squibb Company
 c/o Senior Vice President, Human
Resources
 345 Park Avenue
 New York, NY 10154
 Telephone: (212) 546-4000

		
	Trustee	  	Not applicable
		
	Insurance Company	  	Not applicable

  

 13 

			
	Separation Benefits Plan – Effective September 12, 2006	  	Bristol-Myers Squibb Company

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}]]